Cell therapy weekly: Therapy utilizing fibroblasts against coronavirus receives patent

Written by RegMedNet

Also this week: Stem cell transplant removes active HIV from a patient, Lonza announces collaboration for point-of-care manufacturing and autologous immunotherapy, and Cellectis receives a patent for CRISPR—Cas9 edited CAR-T. Fibroblast cell therapy treatment against coronavirus patented Stem cell transplant leaves second patient with no active HIV particles Cocoon collaboration aims to bring point-of-care manufacturing to autologous immunotherapy Cellectis gains patent for CRISPR-edited CAR-T methodology Fibroblast cell therapy treatment against coronavirus patented FibroGenesis (TX, USA) has filed a US patent for treating the long-term consequences of coronavirus with fibroblast cells. Coronavirus can lead to acute respiratory distress syndrome (ARDS), an...

To view this content, please register now for access

It's completely free